CureVac (NASDAQ:CVAC) Shares Gap Up to $2.44

CureVac (NASDAQ:CVAC) shares gapped up prior to trading on Monday . The stock had previously closed at $2.44, but opened at $2.51. CureVac shares last traded at $2.49, with a volume of 88,287 shares traded.

Analyst Ratings Changes

Separately, Guggenheim reiterated a “neutral” rating on shares of CureVac in a report on Friday, April 5th.

CureVac Trading Up 2.8 %

The firm’s fifty day moving average price is $3.12 and its 200-day moving average price is $4.20. The company has a current ratio of 3.56, a quick ratio of 3.41 and a debt-to-equity ratio of 0.06.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CVAC. Platinum Investment Management Ltd. raised its position in CureVac by 60.6% in the third quarter. Platinum Investment Management Ltd. now owns 363,280 shares of the company’s stock worth $2,481,000 after purchasing an additional 137,146 shares in the last quarter. TD Asset Management Inc raised its position in CureVac by 66.8% in the third quarter. TD Asset Management Inc now owns 209,094 shares of the company’s stock worth $1,428,000 after purchasing an additional 83,747 shares in the last quarter. Jump Financial LLC acquired a new position in CureVac in the fourth quarter worth about $346,000. Dynamic Technology Lab Private Ltd acquired a new position in CureVac in the fourth quarter worth about $160,000. Finally, Aristides Capital LLC acquired a new position in CureVac in the fourth quarter worth about $100,000. Institutional investors and hedge funds own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.